Clinical Trials Search
Clinical Trial 20102
Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT04057040
Phase: Phase II
Prinicipal Investigator: Andrew Kuykendall
Study Title
A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients with Phlebotomy-Requiring Polycythemia Vera
Summary
This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. The study is designed to monitor the PTG-300 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycythemia vera.
Objective
1. Obtain a preliminary estimate of PTG-300s efficacy in phlebotomy-requiring polycythemia vera (PCV) subjects including changes in phlebotomy requirement and splenomegaly. 2. Assess the safety of PTG-300 in PCV subjects who are phlebotomy requiring.
Therapies
Medications
PTG-300 (); Placebo ()
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.